Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as a tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant settings and in metastatic disease.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The product conforms to EU market standards and is manufactured under strict quality controls.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor growth. - Early‑stage hormone receptor‑positive breast cancer: reduces recurrence risk after surgery in postmenopausal women. - Metastatic hormone receptor‑positive breast cancer: slows disease progression in postmenopausal women. - Extended adjuvant therapy after initial treatment: further decreases the chance of cancer returning.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in limbs and back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: intermittent pressure or throbbing pain. - Elevated cholesterol: increase in blood lipid levels.

Serious or Rare Side Effects: - Osteoporosis or severe bone loss: increased fracture risk. - Liver function abnormalities: elevated transaminases. - Cardiovascular events: hypertension or thromboembolic episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Interstitial lung disease: breathing difficulties and cough.

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure patient safety. - Assess bone mineral density: monitor for osteoporosis risk. - Evaluate liver function: check hepatic enzymes before and during therapy. - Screen for cardiovascular risk: monitor blood pressure and lipid profile. - Avoid use in premenopausal women: drug is ineffective without ovarian suppression. - Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels of letrozole. - Concurrent use with tamoxifen: antagonistic effect on estrogen suppression. - Estrogen replacement therapy: counteracts intended action of letrozole.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole exposure. - Anticoagulants (e.g., warfarin): monitor INR as hormonal changes may affect coagulation. - Statins: observe for potential additive liver enzyme elevations.